Developed a female contraceptive in the form of a patch valid the whole month

Scientists are trying to improve almost everything that surrounds us, and contraceptives is not an exception. At the moment women available different types of contraceptives from implantable implant to pills, but they are unlikely to compare with a new development from Georgia Tech. Researchers have created a painless patch with hundreds of microscopic needles that contain contraceptive chemicals. Most interesting is that the patch works for a full month without needing replacement.

Patches with microscopic needles, getting under the skin begin to produce in the blood the active substance has already been used by scientists for delivery to the body’s insulin and even substances for fat reduction. In September 2018, a team of scientists from the University of Washington figured out how this technology is able to save people from the influenza virus is vaccination, they offered to paste on the skin patch that painlessly introduces the necessary vaccine for one day.

Needles patch-contraceptive made from a polymer and a substance called levonorgestrel is the main component of all contraceptives. Polymers are easily destroyed in the body and throughout the month to release the above substance to prevent an unwanted pregnancy. Researchers believe that the patch is much more comfortable than other contraceptives — it can be used alone, but storage does not require special conditions.

The effectiveness of the patch was tested on rats contraceptive effect was seen after the introduction of levonorgestrel contained in hundreds of needles. The substance kept the action for nearly one month. Of course, the person will need the patch with a much larger number of needles and, according to scientists, it is soon to be established and tested. Perhaps in the future the effect of such birth control would last six months.

Researchers understand the potential side effects of the patches — for example, they can cause skin irritation. One of the authors of the study mark Prausnitz hopes that clinical studies will confirm their safety for people.